Norgine signed an exclusive licensing agreement to commercialize Vir Biotechnology’s experimental chronic hepatitis D combination—tobevibart plus elebsiran—in Europe, Australia and New Zealand. The deal hands Norgine regional rights and underscores Vir’s strategy of partnering for geography‑specific commercialization. Financial terms reported included upfront and milestone components; the pact expands distribution options for an orphan viral indication and shows continued appetite among specialty players to license late‑stage antiviral assets for regional markets.